2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2447

Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Abstract Number: 2448

Correlation between Long-Term Low-Dose Steroid Administration and Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis
Abstract Number: 2449

Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry
Abstract Number: 2450

Prosthetic Joint Infection in Patients with Rheumatoid Arthritis
Abstract Number: 2451

Herpes Zoster in Rheumatoid Arthritis. Prospective Single Center Study of 390 RA Patients for 5 YEARS
Abstract Number: 2452

Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
Abstract Number: 2453

Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Abstract Number: 2454

Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
Abstract Number: 2455

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Abstract Number: 2456

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Abstract Number: 2457

Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis
Abstract Number: 2458

Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study
Abstract Number: 2459

Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
Abstract Number: 2460

Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
Abstract Number: 2461

Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].